Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials
Participants with prominent NS revealed greater improvement of NS following KarXT therapy than the full sample that persisted after accounting for positive and other symptoms. While these findings must be interpreted with caution, they are consistent with the possibility that NS improvements associated with KarXT are not secondary to improvements in other symptom domains and support further investigation in larger, stable outpatient studies.
Authors
- Samantha E. Yohn (ORCID: https://orcid.org/0000-0002-3277-4751)
- Inder Kaul
- Stephen K. Brannan (ORCID: https://orcid.org/0000-0003-0922-5970)
- William P. Horan (ORCID: https://orcid.org/0000-0002-0854-6388)
- Steven D. Targum (ORCID: https://orcid.org/0000-0003-1054-5197)
- Amy Claxton
- Stephen R. Marder (ORCID: https://orcid.org/0000-0003-0288-309X)
- Andrew Miller (ORCID: https://orcid.org/0000-0002-4330-320X)
Institutions
- University of California, Los Angeles (US)
- Bristol-Myers Squibb (United States) (US)
Publication Details
- Journal
- Schizophrenia Research
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1016/j.schres.2024.08.001
- Citations
- 39
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 15.04